MedTrace Logo

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

NCT00077636 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1469

Last updated 2016-02-23

Study results available
· View outcomes & findings →

Summary

This study will evaluate the efficacy and safety of different durations of treatment with PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have never previously received interferon (IFN) therapy. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

Copegus

400mg po bid for 16 weeks

DRUG

Copegus

400mg po bid for 24 weeks

DRUG

peginterferon alfa-2a [Pegasys]

180 micrograms sc weekly for 16 weeks

DRUG

peginterferon alfa-2a [Pegasys]

180 micrograms sc weekly for 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2006-03-31
Completion
2006-03-31

Countries

  • United States
  • Australia
  • Canada
  • France
  • Germany
  • Italy
  • New Zealand
  • Puerto Rico
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00077636 on ClinicalTrials.gov